Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14077040 | 0.84 | CYP1A2 (0.49) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL5105688 | 0.79 | RAB9A (0.56) | CYP1A2KDM4EPOLBPIK3CDABL1 | |
| SCHEMBL14557023 | 0.73 | LMNA (0.42) | KDM4ELMNAPOLBDRD2HSD11B1 | |
| SCHEMBL19612589 | 0.72 | HPGDS (0.39) | DRD2DRD3HSD11B1PIK3CDPIK3CA | |
| SCHEMBL14557028 | 0.72 | HSD11B1 (0.34) | DRD2HSD11B1 | |
| SCHEMBL12377969 | 0.72 | DRD3 (0.56) | CYP1A2KDM4EDRD2DRD3KCNH2 | |
| SCHEMBL22815745 | 0.71 | HSD11B1 (0.60) | LMNAHSD11B1 | |
| SCHEMBL4877749 | 0.71 | HSD11B1 (0.39) | CYP1A2DRD3HSD11B1KCNH2 | |
| SCHEMBL1544604 | 0.71 | NPC1 (0.51) | CYP1A2LMNAPOLBHSD11B1 | |
| SCHEMBL2288901 | 0.71 | HSD17B10 (0.56) | CYP1A2KDM4ELMNAPOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003638-B2 | 7-pyrazolylbenzazepines having affinity for D3 receptor | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312213-A1 | 7-Pyrazolylbenzazepines Having Affinity For D3 Receptor | DRD3, HTR3C, GRIN3A | CYP1A2 662/4885KDM4E 2480/4885LMNA 4535/4885 |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | DRD3, DRD2, SLC6A3 | CYP1A2 1169/4885KDM4E 2211/4885LMNA 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.